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Alzheimer’s disease (AD) is characterized by deposi-
tion of -amyloid (A) in diffuse and senile plaques,
and variably in vessels. Mutations in the A-encoding
region of the amyloid precursor protein (APP) gene
are frequently associated with very severe forms of
vascular A deposition, sometimes also accompanied
by AD pathology. We earlier described a Flemish APP
(A692G) mutation causing a form of early-onset AD
with a prominent cerebral amyloid angiopathy and
unusually large senile plaque cores. The pathogenic
basis of Flemish AD is unknown. By image and mass
spectrometric A analyses, we demonstrated that in
contrast to other familial AD cases with predominant
brain A42, Flemish AD patients predominantly de-
posit A40. On serial histological section analysis we
further showed that the neuritic senile plaques in
APP692 brains were centered on vessels. Of a total of
2400 senile plaque cores studied from various brain
regions from three patients, 68% enclosed a vessel,
whereas the remainder were associated with vascular
walls. These observations were confirmed by electron
microscopy coupled with examination of serial semi-
thin plastic sections, as well as three-dimensional
observations by confocal microscopy. Diffuse plaques
did not associate with vessels, or with neuritic or
inflammatory pathology. Together with earlier in
vitro data on APP692, our analyses suggest that the
altered biological properties of the Flemish APP and
A facilitate progressive A deposition in vascular
walls that in addition to causing strokes, initiates
formation of dense-core senile plaques in the Flemish
variant of AD. (Am J Pathol 2002, 161:507–520)
In Alzheimer’s disease (AD), -amyloid (A) is deposited
in two of the most common types of parenchymal depos-
its—diffuse and senile plaques (SPs)—and variably in
vessels [cerebral amyloid angiopathy (CAA)].1 In the
present article, the term “senile plaque” is used to refer to
only classic SPs having a central amyloid core (plaque
core) surrounded by filamentous bundles and granules of
amyloid as well as reactive cells (coronal plaque).2 A is
a cleavage product of the amyloid precursor protein
(APP), produced by the activity of N-terminal -secretase
and C-terminal -secretase (Figure 1). However, the ma-
jor cleavage of APP is by -secretase that cleaves the A
from within and after the sequential -secretase activity,
releases an 3-kd peptide (p3). As yet, all mutations in
APP associated with familial (early-onset) forms of AD
(FAD) or hereditary diseases characterized by CAA are
located around one of the major cleavage sites (http://
molgen-www.uia.ac. be/admutations http://www.alzforum.
org/members/resources/appmutations/apptable. html).3
The majority of the FAD-associated mutations in APP lie
close to its -secretase site, that, similar to FAD-causing
mutations in presenilin (PS) 1 and PS2, increase the pro-
duction of the more amyloidogenic A42 in vitro and in
vivo.3 The only known mutation at the APP -cleavage
site, the double-Swedish mutation (APP K670N/M671L),4
increases in vitro both A40 and A42, although in brain
parenchyma A42 is predominantly deposited.5 Struc-
tural heterogeneity is also noted at the A N-terminus, eg,
A residue R5, E11, or L17 (p3), and such N-truncated
forms are known to be more fibrillogenic and toxic than
full-length A.6,7 Accordingly, N-truncated A42 is pro-
posed to be deposited as early, diffuse plaques8–10 that
seed the deposition of more abundantly secreted A40,
leading to the formation of SPs.11 Despite the anatomical
separation of A deposits and their proposed conse-
quence, viz., intraneuronal accumulation of hyperphos-
phosphorylated tau in dystrophic neurites and neurofibril-
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lary tangles, neuritic pathology is also predominantly
present in the vicinity of SPs and other Thioflavin-S (ThS)-
positive () amyloid deposits, but not diffuse plaques.1,12
The pathological relevance of SPs in AD pathology is
further strengthened by A vaccination strategies in a
murine AD model in which their 50% reduction signifi-
cantly reduces cognitive dysfunction.13
Congophilic or ThS() amyloid deposits in vessels
with primary protein as A (especially A40) is the most
common form of CAA.14 CAA variably occurs in AD,15
however, it is a predominant feature in diseases linked to
APP -cleavage site mutations as in the Dutch
(E693Q),16,17 Flemish (A692G),18 Italian (E693K),19 Arc-
tic (E693G),20 and Iowa (D694N)21 mutations. The Dutch
mutation carriers suffer from hereditary cerebral hemor-
rhage with amyloidosis-Dutch type (HCHWA-D), charac-
terized by recurrent cerebral hemorrhage associated
with parenchymal diffuse deposits, but only rarely SP or
neurofibrillary tangle formation.22–26 In a few HCHWA-D
patients dementia also occurs, which correlates with the
number of amyloid-laden severely stenotic vessels
(ALSSVs).27 However, progressive dementia is a patho-
logical hallmark of Flemish AD (AD/Fl), characterized by
SPs with the largest SP cores in AD, and a severe degree
of neurofibrillary pathology.18,26 Recently identified Arctic
and Iowa mutations also present with clinical AD that has
also been neuropathologically confirmed in one Iowa AD
patient.20,21
The mechanisms by which the mutations on the same
or adjacent codons cause distinct diseases are not fully
understood. Transgenic Dutch and Flemish APP mice
showed that mutant APP/A is toxic, however, brain A
levels in these mouse models did not exceed the critical
level to get deposited.28,29 Most of the knowledge on
these mutations is thus derived from extensive in vitro
modeling. It has been shown that the Dutch mutation
increases A beginning at D1, V18, and Y19, accelerates
A fibril formation and stability, increases in situ aggre-
gation on cultured cell surfaces, and enhances neurotox-
icity to both smooth muscle and endothelial cells.30–37
On the other hand, the Flemish mutation also leads to an
increased production of A beginning at D1, R5, and
E11, proposed to be mediated by a -secretase homo-
logue, BACE 2.38,39 In addition, the Flemish homologue
fibrillizing slower than wild-type A, forms larger and
more stable, neurotoxic aggregates.33,40,41
The purpose of this study is twofold: First, never before
has FAD associated with -secretase site-related muta-
tions been systematically analyzed for type of A depo-
sition. Second, because the plaque cores are the largest
reported in AD/Fl,26 and the biophysical and biochemical
studies suggested that the Flemish A is less aggregat-
able than the wild type, we attempted to identify the under-
lying structures that might initiate the formation of plaque
cores in AD/Fl brains. We first describe here a time-
dependent development of neurofibrillary pathology in a
recently autopsied APP692 family member from whom a
biopsy specimen was also available. Including this patient,
we showed in three APP692 patients a predominant A(1-
40) content of the SPs, suggesting that AD/Fl is not associ-
ated with an increased A42 brain deposition as in other
familial AD. Detailed investigations of SPs in AD/Fl revealed
that the plaque cores were centered on vessels. Our stud-
ies suggest that progressive A40 deposition in vascular
walls in AD/Fl not only results in strokes, but also initiates the
formation of SPs, accelerating neuronal injury to cause the
Flemish variant of AD.
Figure 1. The position of APP mutations in relation to its major cleavage sites and A. Other mutations can be assessed on frequently updated databases
(http://molgen-www.uia.ac.be/admutations and http://www.alzforum.org/members/resources/appmutations/apptable. html).
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Patients and Methods
Family 1302
The APP692 (1302) family is a multigeneration Dutch
family whose members have presenile dementia and ce-
rebral hemorrhage, inherited in an autosomal-dominant
pattern (Figure 2).18 The clinical phenotypes overlap be-
cause hemorrhagic stroke was reported in an offspring of
a demented patient, and conversely, progressive demen-
tia has also occurred in an offspring of a stroke patient.42
Two patients (IV-2 and IV-5) had strokes and were diag-
nosed with AD in their lifetimes, for instance, individual
IV-2 first had dementia at age 41 years and later suffered
a hemorrhagic stroke at age 46 years.42 We earlier stud-
ied two patients who had clinical dementia and fulfilled
the neuropathological criteria of AD (patients IV-4 and
IV-13) (Table 1).18,26,43 Here, we report the neuropatho-
logical analysis of an additional member of the family,
patient IV-5, who had hemorrhagic stroke at age 42
years.18 A biopsy taken while evacuating a large hema-
toma in the left parieto-occipital cortex, revealed CAA
and both senile and diffuse plaques, however, neurofi-
brillary tangles or hyperphosphorylated tau (AT8)-posi-
tive neurites were absent. Consistently, before the intra-
cerebral hemorrhage, this patient did not show any signs
of cognitive impairment. However, in the course of dis-
ease, the patient developed progressive dementia and at
age 48 years was diagnosed with dementia indistinguish-
able from AD.42 The patient slowly progressed to a veg-
etative state and died at age 55 years. The brain was
fixed in 4% formaldehyde and analyzed.
Histology Including Immunohistochemistry
Examination of the brain of patient IV-5 was performed
after a postmortem interval of 51⁄2 hours. The right cere-
bral hemisphere was fixed by immersion in 10% formalin
and embedded in paraffin. Five-m thick sections were
taken from superior frontal gyrus, superior temporal gy-
rus, superior occipital gyrus, superior parietal lobule, hip-
pocampus and entorhinal cortex, basal ganglia, midbrain
with substantia nigra, pons, cerebellum, brain stem, and
cervical spinal cord. Sections were examined by routine
histopathological methods and also with Thioflavin S
(ThS), Congo red, Cresyl violet, periodic acid-Schiff, and
Bielschowsky.
For A subspecies identification and other immunohis-
tochemistry (Table 2), serial 4- to 5-m sections were
sliced from the hippocampus, superior temporal gyrus,
superior frontal gyrus, and cerebellum of the following
cases: three AD/Fl patients (IV-4, IV-5, and IV-13), spo-
radic AD patients (n  5), AD with PS1 mutations (I143T;
n  5 and A384A; n  5), and a HCHWA-D patient.
For immunohistological study of the SPs in three AD/Fl
patients, serial 2- to 3-m-thick sections were sliced from
paraffin-embedded blocks of the superior frontal gyrus,
superior temporal gyrus, and cerebellum. On an average,
500 sections were sliced from each block. The sections
were double immunostained with A antibodies and
blood vessel markers [CD31, CD34, smooth muscle actin
or collagen type IV (C-IV)] (Table 2). From the two neo-
cortical and one cerebellar region, 300 and 200 SPs,
respectively, from each patient (n  3) were serially
Figure 2. Family 1302 pedigree. The pedigree is disguised for reasons of confidentiality. Roman numbers are the generations and affected individuals are
numbered on the upper corner. The proband is indicated with an arrow and an asterisk indicates individuals in which autopsy is performed. Upper half-filled
symbols represent patients presenting with AD, and lower half-filled symbols, with cerebral hemorrhage. Few patients had strokes and were also diagnosed
to have AD (filled symbols). Patients IV-4 and IV-13 have been previously confirmed to have AD pathologically.26 Dementia in individual III-16 was because
of unrelated etiology as the mutation was absent here.
Table 1. Clinical Events and Neuropathological Changes Noted in Three Autopsied Patients of the APP692 Family
APP692
patients Biopsy Autopsy First presentation
AAO
(years)
AD
(Braak staging)
Severe degree
of CAA ApoE* Reference
IV-4   Progressive dementia 49  (V/VI)  3/4 26
IV-5   Stroke 42  (V/VI)  3/4 18 and this report
IV-13   Progressive dementia 48  (V/VI)  3/3 26
*There is no evidence that APOE modifies the disease onset for this family.79 AAP, age at onset.
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imaged by a digital charge-coupled device color camera
(Sony Corporation, Tokyo, Japan) connected to a Vidas
image analysis frame grabber (Kontron, Mu¨nchen, Ger-
many). SPs and other amyloid deposits were serially
studied. SPs were so addressed if on any section had the
appearance exemplified (Figures 3 and 4), thus closely
resembling such deposits in other familial and sporadic
AD patients (Figure 3L).
Antigen retrieval for A immunohistochemistry was
performed on sections treated in 98% formic acid for 5
minutes at room temperature. All dilutions were made in
0.1 mol/L of phosphate-buffered saline with 0.1% bovine
serum albumin. Staining for single antigen was per-
formed using streptavidin-biotin-horseradish peroxidase
using chromogen 3,3diaminobenzidine (Roche Diag-
nostics, Vilvoorde, Belgium), described previously.29 Im-
munohistochemistry involving detection of more than one
antigen was done using species-specific or IgG subtype-
specific secondary antibodies, conjugated directly to biotin,
horseradish peroxidase, alkaline phosphatase, or galacto-
sidase (Southern Biotechnology, Birmingham, AL). This was
followed by color development using one of the following
chromogens (acquired from Roche): 3,3diaminobenzi-
dine, 3-amino-9-ethylcarbazole, Fast-red, 5-bromo-4-
chloro-3-indolyl-phosphate/nitroblue tetrazolium solution, or
5-bromo-4-chloro-3-indolyl-D-galactopyranoside (X-gal).
Different cycles of primary, secondary, and tertiary antibod-
ies, and of chromogens were used during double-
immunohistochemical staining to avoid bias of staining for
any one particular antibody.
Using antibodies specific for A N-terminus (eg,
6E10), and contrasting with reactivity for A17–24 (4G8),
distinguished full-length and N-truncated A, as de-
scribed previously.44 Specificity of A antibodies was
examined by dot blotting using 50 ng of synthetic wild-
type, Flemish, and Dutch A peptides either as full-length
A (Biosource, Nivelles, Belgium) or N-truncated A (12–
42) peptide. Although 4G8 recognized the Flemish and
Dutch A less avidly compared to the wild type, no
difference was observed for any N- or C-terminus A
antibody used in this study, or between any full-length
wild type, or mutated A40 or A42, and their corre-
sponding N-truncated forms (data not shown).
Fluorescence and High-Resolution Transmission
Electron Microscopy
Labeling for confocal laser-scanning microscopy was
done on 10- to 50-m-thick sections incubated overnight
Figure 3. Flemish AD (AD/Fl) pathology. Biopsy analysis of the occipitocortical region of patient IV-5 stained for antibodies against 4G8 and AT8 (A) and
ubiquitin (B). Autopsy analysis of the same patient of the occipitocortical region with AT8 (C) and of hippocampus with AT100 (D). Micrographs (E–H) illustrate
the repertoire of ThS() plaques in AD/Fl stained with 4G8: a SP with a central plaque core surrounded by a coronal plaque (E). Note in the upper half of this
illustration a small SP that otherwise resembles dyshoric angiopathy; multicentric SP (F); CAA with its perivascular plaque (G); and primitive plaques (H). I: A
cortical region to demonstrate a recent hemorrhage associated with affected vessels. J: Histochemical stains bound avidly to SP dense core regions (arrow) but
not coronal plaque (arrowheads; whereas with A immunohistochemistry, the edges of the plaque core stained stronger compared to its centers (K; compare
with J). A similar immunohistochemical pattern was observed in sporadic AD brain (L). M: Association of microglia (CD68, brown) with plaque cores as well as
with amyloid-laden severely stenotic vessel (ALSSVs, blue). N: Association of astroglia (GFAP, red) with SP (blue). O: Vascular endothelial growth factor reactivity
in association with an ALSSV. P: A neurocentric diffuse plaque. c, Plaque core. Scale bars: 50 m (A–C); 100 m (D); 40 m (E–P).
Table 2. Antibodies Used in the Characterization of SP in AD/Fl Patients
Antibody Epitope/marker Type Dilution Antigen retrieval Reference
4G8 A residues 17–24 IgG2b 1:20,000 Formic acid Senetek, Maryland Heights, MO
6E10 A N-terminus;
recognizes A 5–11
IgG1 1:10,000 Formic acid Senetek
6F3D A N-terminus IgG1 1:25 Formic acid Dako, Glostrup, Denmark
JRF/AN/11 A N-terminus IgG2a 1:500 Formic acid Gift from M. Mercken
JRF/cAb40/6 A40 IgG2a 1:500 Formic acid Gift from M. Mercken
R209 A40 pAb-rabbit 1:400 Formic acid Gift from P. Mehta
FCA3340 A40 pAb-rabbit 1:150 Formic acid Gift from F. Checkler
JRF/cAb42/12 A42 IgG1 1:500 Formic acid Gift from M. Mercken
FCA3542 A42 pAb-rabbit 1:250 Formic acid Gift from F. Checkler
R226 A42 pAb-rabbit 1:400 Formic acid Gift from P. Mehta
AT8 Abnormally
phosphorylated tau
IgG1 1:20,000 — Gift from Innogenetics,
Zwijraarde, Belgium
Anti-CD31 Endothelium IgG1 1:100 Citrate buffer JC70; Dako
Anti-CD34 Endothelium IgG1 1:100 Citrate buffer QBEnd/10; Dako
Anti-SMA Smooth muscle cell
actin
Citrate buffer Dako
Anti-collagen type IV Vascular basement
membrane
IgG1 1:50 Citrate buffer Dako
Anti-GFAP Glial fibrillary acidic
protein
IgG1 1:1000 Citrate buffer Dako
Anti-CD68 Macrophage IgG3 1:100 Pronase digestion Dako
Anti-ubiquitin Ubiquitin pAb-rabbit Citrate buffer Dako
Anti-C1q complement Complement cascade pAb-rabbit 1:100 Citrate buffer Dako
Anti-HLA-DP,DQ,DR Complement cascade IgG1 1:100 Citrate buffer Dako
Anti-VEGF Angiogenesis pAb-goat 1:100 Citrate buffer R&D Systems, Abingdon, UK
Anti-bFGF Angiogenesis pAb-goat 1:100 Citrate buffer R&D Systems
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with 4G8, or mouse A40 or A42 antibody, washed and
labeled with an anti-mouse tetramethylrhodamine B iso-
thiocyanate-conjugated antibody (Molecular Probes, Eu-
gene, OR). For multiple labeling, sections were co-incu-
bated overnight with rabbit anti-A40 or anti-A42 and
mouse IgG1 against vessel components (varied combi-
nations of CD31, CD34, smooth muscle actin, and or
C-IV), washed, and labeled with an anti-mouse tetra-
methylrhodamine B isothiocyanate conjugate and an an-
ti-rabbit fluorescein isothiocyanate antibody. Images
were acquired with a Zeiss CLM-410 (Carl Zeiss NV-SA,
Zaventum, Brussels) using either 488 nm line of argon
single laser or 632 nm helium-neon double laser for ex-
citation. Three-dimensional reconstructions were made
by AnalySIS (Soft Imaging System, Mu¨nster, Germany).
Araldite blocks of neocortex, hippocampus, and cer-
ebellum of patients IV-4 and IV-13 were used for elec-
tron microscopy. Immersion fixation was achieved with
4% neutral buffered glutaraldehyde followed by 2%
buffered osmium tetraoxide. Blocks were sectioned
with a Reichert Jung microtome (Leica, Wein, Austria)
equipped with a section counter, and ribbons of 0.25-
m-thick sections of small regions of interests were
collected on copper grids. Sections were contrasted
with routine uranyl acetate and lead citrate, and 20 SPs
were analyzed by a Philip CM10 electron microscope
(Philip, Eindhoven, The Netherlands) equipped with a
goniometric coordinator. The ultra-thin sections were
interspersed with thicker 1-m sections collected on
glass slides for light microscopy.
Morphometric, Densitometric, and Mass
Spectrometric Analyses
Morphometric and densitometric analyses were done by
a self-written software on a Vidas Image Analysis System,
described previously.45 Sizes of SPs and CAA (n  300
each) from various regions of AD/Fl patients were mea-
sured and compared by a two-tailed unpaired t-test.
Amyloid-laden vessels were ascribed severely stenotic
when the ratio of the lumen diameter and the vessel
diameter was less than one half.
For A subspecies identification, sections were
stained with different A40 and A42 antibodies (Table
2). Semi-interactive quantification was done as de-
scribed45 and the percentage areas of reactivity in ves-
sels and parenchymal plaques were assessed.
Isolation of A from meningeal vessels in AD/Fl and
sporadic AD brains, frozen at 70°C, was performed as
described46 with slight modification. Different parenchy-
mal amyloid deposits were carefully extracted with tissue
microdissection aided by immunohistochemistry on ad-
jacent sections. Samples were thawed and washed three
times in ice-cold Tris-buffered saline and homogenized in
a buffer of 150 mmol/L NaCl, 50 mmol/L Tris-HCl, pH 8.0,
containing protease inhibitors (ethylenediaminetetraace-
tic acid-Na, 2 mmol/L; leupeptin, 10 mol/L; pepstatin, 1
mol/L; phenylmethyl sulfonyl fluoride, 1 mmol/L; TLCK,
0.1 mmol/L; TPCK, 0.2 mmol/L). The homogenates were
centrifuged at relative centrifugal force (RCF) 100,000 
g for 1 hour and brain tissue pellets were washed three
times with ice-cold Tris-buffered saline and then ex-
tracted using 1.0 ml of 70% formic acid by sonication and
vortexing for 2 hours at 4°C. The formic acid extracts
were centrifuged at 100,000  g for 2 hours and the
formic acid layers were collected and stored at 20°C.
From these samples, A was immunoprecipitated using
4G8 and protein G Plus/Protein A agarose beads (Onco-
gene Science, Inc., Cambridge, MA) and analyzed using
a matrix-assisted laser-desorption/ionization-time-of-flight
(MALDI-TOF) mass spectrometer (Voyager-DE STR Bio-
Spectrometry Workstation, PE/PerSeptive Biosystem) de-
scribed previously.47,48
Results
Pathological Confirmation of AD for Patient IV-5
Weight of the brain at autopsy was 855 g and showed
atrophy of all cortical areas. Old cystic infarcts were
present in temporal and occipital cortices bilaterally. Mi-
croscopic examination of the right cerebral hemisphere
revealed diffuse cortical atrophy and microspongiosis of
upper cortical layers. Silver impregnation and A immu-
nohistochemistry revealed a huge load of CAA, SPs with
large plaque cores, and diffuse plaques, in hippocam-
pus, parahippocampus, neocortex, basal ganglia, and
cerebellum. Amyloid deposits were manually counted on
4G8-stained sections by a Zeiss MC80 microscope
equipped with an ocular graticule and a 10 objective
(1.56 mm2). On an average, 10 SPs were present in the
gray matter fields of all neocortical regions as well as in
hippocampus, and 4 SPs were present in basal gan-
glia, substantia nigra, and cerebellum. In other brain
regions, including the central gray matter of the spinal
cord, at least some forms of ThS() plaques were ob-
served. AT8() dystrophic neurites and neuropil threads
Figure 4. Morphometric image analysis in AD/Fl brains for SPs (A) and
amyloid-laden severely stenotic vessels (ALSSVs) (B). Neither the sizes of
CAAs and SPs, nor the percentage areas occupied by perivascular and
coronal plaques in CAAs and SPs, respectively, were significantly different
(P  0.2). For this analysis, SPs with only one central core were considered
(arrow) and atypical SPs, eg, with an eccentric core (arrowhead) were
disregarded. Scale bars, 40 mm.
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were also present in varying severity in all regions except
cerebellum, where only Ubi() dystrophic neurites were
observed. Especially in the neocortical and hippocampal
regions, both SPs and CAA were equally associated with
Ubi() and AT8() dystrophic neurites in the surround-
ing parenchyma. Silver impregnation also recognized a
large number of neurofibrillary tangles in hippocampus
and neocortex. Based on the presence of tangles in all
sectors of hippocampus and subiculum as well as a
severe involvement of isocortex, the brain was as-
signed Braak and Braak49 stage V/VI (Table 1 and
Figure 3; A to D).
AD/Fl Pathology
Core-containing SPs and coreless primitive plaques were
the most abundant plaques in the neocortical and limbic
areas in the three AD/Fl brains, where they were far more
common in the gray, than in the white matter (Figure 3; E
to H). SPs were associated with unusually large plaque
cores and were also sometimes multicentric. However, a
small number of SPs had a relatively smaller plaque core
size compared to the surrounding coronal plaque and
thus closely resembled SPs commonly described in
AD.2,26 SPs were also predominantly present in the gran-
ular layer of cerebellum. The primitive plaques as de-
scribed elsewhere2 were circumscribed clusters of
ThS() amyloid wisps without a central dense core and
also had a striking textural resemblance to the perivas-
cular and coronal plaques.
A huge load of amyloid was also deposited in capillar-
ies and small- to middle-sized arteries often displaying
vessel-within-vessel configurations and frequently asso-
ciated with microvascular changes such as microaneu-
rysms, fibrinoid necrosis, and small hemorrhages (Figure
3I). These microvascular changes have earlier been ob-
served in HCHWA-D patients in which they correlate with
the severity of the amyloid angiopathy.50 The perivascu-
lar amyloid plaques, however, were different in the AD/Fl
and HCHWA-D brains. Whereas in AD/Fl, copious
perivascular amyloid deposits were often seen in asso-
ciation with severely affected vessels, such deposits
were minimal to absent in HCHWA-D. Even in HCHWA-D
patients with one of the most severe degree of CAA,
severely stenotic vessels were not shown to be associ-
ated with appreciable perivascular plaque pathology.27
Figure 5. Immunohistochemistry to differentiate A40 from A42 (A, C) or of full-length A from N-truncated forms (B, D) in the neocortex of AD/Fl (A, B) and
HCHWA-D patients (C, D). A that stained with 4G8, but not with antibodies against the first five residues was interpreted as being N-truncated. Diffuse plaques
were solely composed of N-truncated A42 (blue in A and B and red in C and D); whereas SPs and CAAs were predominantly composed of full-length A40
(brown in A and B and purple in C and D). E: A higher magnification of the A40 and A42 distribution in SPs in an AD/Fl patient. F: Image analysis for A40
and A42 within SPs and CAAs in AD-Fl patients, a single patient of HCHWA-D, two different PS1 mutations, and sporadic AD patients (n 5 each), by antibodies
FCA3340 and FCA3542. Other A C-terminal antibodies offered similar results. Scale bars, 40 m (A–E).
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We further observed a different binding pattern of SP
subcomponents for histochemical and immunohisto-
chemical reagents (Figure 3, J and K). The histochemical
dyes such as Masson’s trichrome bound less avidly to the
coronal, perivascular, and the primitive plaques, but in-
tensely to the plaque cores, especially to their center-
most regions. By contrast, the most peripheral regions of
the plaque cores, and also the coronal, perivascular, and
primitive plaques, stained strongly with A immunohisto-
chemistry. Such A reactivity pattern is not uncommon
for SPs in sporadic or other familial AD.
We studied the association of different plaques in
AD/Fl brains with hyperphosphorylated tau (AT8) and
reactive glial pathology by double immunohistochemis-
try. As described earlier,25,51 CAA in HCHWA-D was
associated with only Ubi() dystrophic neurites. By con-
trast, an equal association of both SPs and CAA in AD/Fl
brains was observed with not only Ubi() dystrophic
neurites, but also AT8() dystrophic neurites, along with
a prominent glial and inflammatory pathology (Table 2
and Figure 3, D, M, and N). Staining AD/Fl brains with
angiogenic markers such as vascular endothelial growth
factor or basic fibroblast growth factor, a strong reactivity
was observed in the vicinity of severely occluded vessels
(Figure 3O). Diffuse plaques in AD/Fl, similar to those
described in other AD as well as in HCHWA-D pa-
tients,2,23 did not consistently associate with a neuritic,
glial, inflammatory, or angiogenic pathology (Figure 3P).
Morphometric Analysis for AD/Fl Brains
Perivascular plaques, especially those associated with
amyloid-laden severely stenotic vessels (ALSSVs) had a
striking resemblance to the coronal plaques. We used
image analysis to assess sizes of SPs and ALSSVs, the
latter defined as when the vessel lumen diameter/CAA
diameter was less than or equal to one half. Both ALSSVs
and SPs ranged from a few to 600 m in diameter and the
average diameter (SD) of ALSSVs was 53.4 m (43.3)
and not significantly different from that of the plaque
cores (51.6 48.8 m, P 0.3). Furthermore, comparing
the ratios of the perivascular and coronal plaque areas to
their respective total ALSSV and SP areas, the perivas-
cular plaques constituted 43.2% (16.4) of ALSSVs,
which was not significantly different from the proportion of
coronal deposits constituting SPs (49.2  18.3%; P 
0.2) (Figure 4).
Predominant A40 Composition of SPs
To identify the precise A species deposited in brains of
AD/Fl patients, and also to explore the constitutional sim-
ilarities of amyloid deposits between AD/Fl, HCHWA-D,
and PS1 and sporadic AD patients, serial brain sections
were stained with antibodies specific for C-terminal A40
or A42, A N-terminus, and the middle portion of A
(A17-24; 4G8). Double immunohistochemistry for these
antibodies in various combinations revealed a predomi-
nant A(1-40) content of CAA and plaque cores, and a
comparable reactivity for A(1-40) and N-truncated A42
in the perivascular and coronal plaques. Diffuse plaques
in AD/Fl were entirely composed of N-truncated A42,
again resembling diffuse plaques present in the familial
and sporadic AD, as well as in HCHWA-D patients.5,8
Percentage areas of plaques stained by A40 and A42
were studied on serial brain sections using an image
analysis program. A40 was the predominant amyloid in
vessels in AD/Fl patients (77%), sporadic AD patients
(67%), PS1 mutation carriers (60%), and HCHWA-D pa-
tients (71%). A40 also constituted a major fraction of A
in parenchymal deposits in AD/Fl patients (66%), but only
a minor fraction in sporadic and PS1 AD (23% and 26%,
respectively) and being completely absent in HCHWA-D
patients (Figure 5).
Quantification of the relative amounts of A42 and
A40 was done by MALDI-TOF mass spectrometry on A
immunoprecipitated from frozen AD/Fl brain extracts with
Figure 6. Formic acid extracts of A deposited in brain, immunoprecipitated
with 4G8, and analyzed by MALDI-TOF mass spectrometry. From an AD/Fl
patient, A extracted from (A) SPs and (B) CAAs revealed a major peak at
A(1-40). C: A familial AD (PS1 G384A) brain analysis for a neocortical
region enclosing predominantly diffuse plaques. Peaks corresponding to A
are labeled with their amino acid sequence numbers. Peaks marked p3-x and
p11-x represent peptides beginning with pyroglutamic acid (pyroGlu-3 or
pyroGlu-11). Ins2 peak corresponds to a doubly charged ion of insulin
used for mass calibration.
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4G8 that does not distinguish between A40 and A42.
Full-length A was the major peptide identified in SPs
with a 25-fold abundance of A(1-40) greater than A(1-
42). Mass spectrometric analysis of amyloid-laden ves-
sels extracted from the brains of Flemish and sporadic
AD patients also showed respective 32- and 10-fold
higher levels of A(1-40) than A(1-42). However, con-
sistent with earlier observations,52 analyses of different
regions from familial and sporadic AD brains showed that
diffuse plaques, but not SPs, were predominantly com-
posed of A(1-42) and A(11-42) (Figure 6).
Vasocentric SPs in the Flemish AD
Confocal laser-scanning microscopy using A40- and
A42-specific antibodies showed all A40() plaques to
be positioned around microvessels (positive for CD31,
CD34, smooth muscle actin, or C-IV). Three-dimensional
reconstructions further displayed a close relationship of
amyloid-laden vessels and plaque cores, and the abrupt
development of CAA at their points of branching (Figure
7, A and B). Light microscopic examination of plastic
1-m-thick serial sections stained with toluidine blue also
demonstrated a close relationship of vessels with plaque
cores (Figure 7C). Double immunohistochemistry for A
and vessel markers revealed the presence of a central or
paracentral vessel within 68% of the 2400 SPs studied
(Table 3; Figure 8), whereas the remaining were closely
associated with the vascular basement membranes of
comparatively large-caliber vessels. Most of the primitive
plaques enclosed a plaque core or an amyloid-laden
vessel in serial section analysis.
Serial ultra-thin section examination revealed a radial
arrangement of A fibrils projecting from the basement
membrane into the surrounding neuropil as has been
classically described for dyshoric angiopathy.53 With
larger vessels, this phenomenon was often limited to only
a part of the vessel and core-like compact structures
seemed to evolve from the vascular basement mem-
branes (Figure 9). The gruel of these larger amyloid de-
posits or also amyloid deposited abluminally was amor-
phous, or haphazardly arranged in loose bundles,
whereas the amyloid at core-periphery was radially ar-
ranged in filamentous bundles. As interpreted from light
microscopic studies, the compact amyloid at the center
bound more avidly to histochemical stains, whereas the
peripheral radial spicules bound more intensely to A
antibody; the latter could be because of a relative acces-
sibility of A epitopes.
The noncongophilic diffuse plaques did not have any
consistent relationship with vessels, although small amy-
loid-laden vessels were sometimes noted in these plaque
deposits, as has also been observed earlier.26 Many of
these diffuse plaques were also associated with neurons
(Figure 3P).
Figure 7. Confocal microscopic (A, B), and serial semi-thin plastic sections study (C). A and B: Neocortical regions demonstrating continuation of SP (closed
arrows) into vessels (open arrows). Note that plaque cores develop at points of vessel branching (arrowheads in A). C: An example of SPs analyzed in the
granular layer of cerebellum showing a vascular link. c, Plaque core; *, coronal region. Scale bars, 100 m.
Table 3. Proportion of SPs Enclosing a Central or Paracentral Vessel Recognizable by Vessel Markers on Serial Section Analysis
APP692
patients
Superior temporal
cortex (n  300, each)
Superior frontal cortex
(n  300, each)
Cerebellum
(n  200, each)
Total
(n  2400)
III-4 212 (70.7%) 199 (66.3%) 169 (84.5%)
III-5 166 (55.3%) 176 (58.7%) 164 (82.0%) 1626 (67.8%)
III-13 204 (68.0%) 190 (63.3%) 146 (73.0%)
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Discussion
In this study, we first demonstrate that irrespective of the
initial clinical presentations of stroke or progressive de-
mentia, the end-stage neuropathology of APP692 pa-
tients is remarkably similar. In all these patients, unusually
large SP cores and a severe degree of CAA are associated
with severe neurofibrillary pathology in neocortical and lim-
bic regions (reference 26 and this report). We next showed
a predominant A40 content of SPs in AD/Fl brains by
image and MALDI-TOF mass spectrometric analyses.
These data are in sharp contrast to other familial and spo-
radic AD brains, where predominantly A42 is deposited.3
In recently identified Iowa AD patients, appreciable
amounts of A40 were also noted in SPs in one patient,21
however, it remains to be studied whether A40 similarly
constitutes predominant amyloid deposit in these brains as
well. This increase in deposited A40 in patients with mu-
tations near the -secretase site might be in part because of
an alteration of APP processing distinct from those caused
Figure 8. Serial section study by double immunohistochemistry with A antibody 4G8 (blue) and a combination of endothelial cell marker CD31 and CD34
(brown), in superior frontal cortex (A), superior temporal cortex (B–C), and cerebellum (D), from patients IV-4 (A, B), IV-13 (C), and IV-5 (D). Almost all dense-core
SPs shown here are associated with vessels, with indication that SPs might occur at the points of vascular branching (arrowheads). Scale bars, 40 m.
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by - or -secretase site APP mutations. For instance, it has
been shown that in contrast to the increased in vitro A42/
A40 noted for the -secretase cleavage site-related APP
mutations or mutations in PS,3,54 Flemish APP transfectants
in CHO-K1 and H4 cells do not alter the relative levels of
A(1-40) and A(1-42).55 This actually holds true for all
N-truncated A forms secreted from HEK-293 Flemish
transfectants and analyzed by MALDI-TOF mass spectrom-
etry (S Kumar-Singh, R Wang, C De Jonghe, and C Van
Broeckhoven; unpublished results). Instead, the effect of
the Flemish mutation is observed on A N-terminus pro-
cessing, in which relative to the wild type, an increase in A
(2-fold) and in A N-truncated at F19 and F20 occurs.38
This has been proposed to be partly because of an in-
creased BACE2 activity.39 In brains of AD/Fl patients, how-
ever, we identified only A(1-40). To confirm that a minor
proportion A(1-42) and N-truncated forms of A in AD/Fl
brains was not because of their added aggregative prop-
erty,6 we showed in the same set of experiments a predom-
inance of highly fibrillogenic A(1-42) and A(11-42) in
mutant PS1 brains, data consistent with a recent report.52
Thus, an unaltered Flemish APP processing at the A C-
terminus, leading to a normally occurring nine times higher
proportion of A40 correlates well with classical AD/Fl pa-
thology in the form of a severe degree of CAA and large SP
cores—the only deposits known to comprise predominantly
A40 in AD.12,15,26
The observed dimensional, morphological, and consti-
tutional similarities between amyloid-laden vessels and
SPs in AD/Fl further suggested that these A deposits
represent a spectrum of the same etiopathogenic pro-
cess. Scholtz56 first observed that plaque cores were
intimately related to material permeating from vessels.
Many groups since then either suggested a vascular
origin of SPs and/or diffuse plaques,57–63 or proved the
contrary.64–68 (Figure 10). In this study, we convincingly
demonstrated that at least in one form of AD, SPs but not
diffuse plaques are centered on vessels. A proportion of
amyloid cores enclosing a vessel refutes a co-incidental
relationship, for instance, the likelihood of endothelial cell
proliferation into any established plaque cores is remote,
taken the compactness of such structures and the toxic
nature of amyloid on potential budding endothelial cells.
In other words, 68% of SPs so addressed were ALSSVs
examined paracentrally to their existing lumen. The re-
maining 32% were associated with vascular walls and
further suggested that one of the components of vascular
basement membrane seed the formation of these SPs.
Figure 9. Serial section study by electron microscopy. Examination of ultra-thin serial sections revealed a close link of SPs with vessels exemplified here in two
series. A: Plaque P2 on follow-up was shown to have an eccentric vessel within the plaque core. Similarly plaque P1 was also shown in other sections to enclose
a vessel within (not shown). B: Amyloid-free vessel followed serially was linked to an amyloid deposit (identified on semi-thin sections as SPs). Note the continuity
of vascular basal lamina around compact amyloid (arrow). Scale bars, 20 m.
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Alternatively, these might also represent A occluding
smaller vascular branches because CAA is shown to
initiate at points of vascular branching.69
Interestingly, some of the aspects of Flemish AD pa-
thology have been reproduced in vitro. It has been shown
that Flemish A although aggregating slower than the
wild type, however, progress to form exceptionally large
and insoluble amorphous aggregates.40 Recent studies
have also suggested that the aggregates formed by
Flemish A are as neurotoxic as those formed by the
wild-type A.41 An increase in the number and size of
vascular Flemish A deposits is also supported by a
model based on observations that the Flemish mutation,
but not Dutch, affects a string of amino acids (A17-21)
that govern the A nucleation-dependent polymerization
process.19,70 However, the evolution of vascular A de-
posits in AD/Fl brains to form SPs remains elusive and so
is the precise mechanism of formation of CAA. The orig-
inal suggestion that CAA forms entirely from vascular
smooth muscle cells,71 remains disputed.72 An alternate
suggestion that vascular A is derived from parenchymal
sources draining with interstitial fluid along the periarterial
pathways72 is supported by studies on transgenic mice
in which neuron-derived A is sufficient to cause CAA.73
Formation of large SPs in AD/Fl can thus be most con-
vincingly explained by an increased neuronal secretion
of Flemish A with slower aggregation kinetics, facilitat-
ing its extensive permeation along the interstitial fluid to
form not only vascular deposits, but extensive perivascu-
lar/coronal deposits as well.
Notwithstanding the role of CAA in causing neural
toxicity through the formation of SPs, if one accepts a
primary parenchymal amyloid pathology to instigate a
secondary neuritic pathology, then severely affected
amyloidotic vessels should also be directly capable of
causing neuritic pathology and therefore progressive de-
mentia. In a striking illustration, progressive senile de-
mentia has also been described in two patients with
APOE 4/4 genotype in the complete absence of amyloid
plaques, but in the presence of a severe degree of CAA
associated with both perivascular amyloid plaques and
neurofibrillary pathology.74 Also, it was recently demon-
strated that a severe degree of CAA and an increased
number and size of SPs strongly correlates with muta-
tions in PS1 after codon 200.75 In some of these muta-
tions where CAA is prominent, both CAA and SPs are
equally associated with all pathological hallmarks of
AD.76 In this light, an equal association in AD/Fl brains of
SP and CAA with neurofibrillary, gliotic, and inflammatory
pathology was not surprising. However, the precise rea-
son for a complete absence of neurofibrillary degenera-
tion in association with ThS() CAA in HCHWA-D pa-
tients remains elusive. It could either be because of the
specific A mutation or the relative absence of perivas-
cular amyloid noted in HCHWA-D vascular amyloidosis. If
the latter is relevant, it might suggest that development of
perivascular/coronal plaques could be a critical factor
that temporally governs the development of neuronal tox-
icity and therefore clinical dementia. A time-dependent
association of parenchymal amyloid to instigate a neuritic
pathology77 occurs in patient IV-5. This patient showed a
complete absence of neurofibrillary pathology at the time
of biopsy despite the presence of abundant SP cores
(associated sometimes with small-sized coronal plaques)
and CAA,18 however, on autopsy elicited a full-blown
neuritic pathology in all neocortical and limbic regions
analyzed.
Besides a direct A induced toxicity, CAA is also
known to cause cerebral hypoperfusion in AD.78 In dis-
ease in which CAA is prominent, vascular hypoperfusion
could be sufficiently severe to impact on the final demen-
tia phenotype. For instance, progressive dementia in a
minority of HCHWA-D patients has been correlated with
the most severe degree of CAA.27 White matter lesions
present in young APP692 presymptomatic carriers42 as
well as a hypoxic neoangiogenic response as we show in
this study, suggests a third mechanism by which CAA
might cause progressive dementia syndrome in AD/Fl
patients.
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